Sign in
Not yet recruitingNo phase

HOPE-Sepsis: Hemoadsorption Therapy for Sepsis

Key facts

Who runs it
Shanghai Zhongshan Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
30 people, planned
Started
1 Oct 2026
Expected to end
31 Mar 2028
Type of study
Interventional
Treatments tested
  • Hemoperfusion with CA330 Cytokine Adsorption Column
Record updated
8 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Age ≥18 years. Sepsis (Sepsis-3): Diagnosis of sepsis according to Sepsis-3 criteria. Blood IL-6 >100 pg/mL, Expected ICU stay >48 hours. Informed consent obtained from the patient or legally authorized representative

Who cannot take part

  • Immunosuppressed state, such as receiving immunosuppressive therapy or HIV infection
  • Pre-existing chronic kidney disease or end-stage renal disease. Pregnancy or lactation. Refusal to participate in the study
  • Severe coagulation dysfunction, including platelet count <50 × 10⁹/L or significantly prolonged PT/APTT

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single-center, prospective, single-arm, open-label study that will enroll 30 adult patients with sepsis at Zhongshan Hospital, Fudan University. All participants will receive CA330 hemoadsorption in addition to standard care. Blood samples will be collected at prespecified time points before hemoadsorption (T0), immediately after completion of hemoadsorption (T1), and approximately 24 hours after completion of hemoadsorption (T2) to evaluate changes in IL-6 and other inflammatory biomarkers. TMT-based quantitative proteomics will be performed on plasma samples collected at T0 and T1 to characterize acute treatment-associated molecular changes and explore their relationships with clinical outcomes.

The group in the trial

  • Hemoadsorption ArmTreatment being tested

    Participants will receive CA330 hemoadsorption in addition to standard care for sepsis. Blood samples will be collected at T0 (before hemoadsorption), T1 (immediately after completion of hemoadsorption), and T2 (24 ±2 hours after treatment) for biomarker assessment. Plasma proteomics will be performed using samples collected at T0 and T1.

    Treatment: Hemoperfusion with CA330 Cytokine Adsorption Column

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Proteomic Analysis and Clinical Efficacy Evaluation of Hemoadsorption Therapy in Sepsis
Record updated
8 October 2026